Evidence map›Paper›PMID 40512820›Full record

ArticlePLoS genetics2025

Visualizing androgen signaling and assessing its interaction with canonical Wnt signaling pathways in prostate development, morphogenesis, and regeneration.

Yao Mawulikplimi Adzavon, Dong-Hoon Lee, Alex Hiroto, Tae Ju Park, Gaeul Chu, Yunjeong Kim, Kristoffer Nikias, Cheong-Wun Kim, Dexter Hoi Long Leung, Chenmiao Liu and 2 more

Abstract read
In one paragraph

Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yao Mawulikplimi AdzavonDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Dong-Hoon LeeDepartment of Cancer Biology and Molecular Medicine, Cancer Center and Beckman Research Institute, City of Hope Medical Center, Duarte, California, United States of America.
Alex HirotoDepartment of Cancer Biology and Molecular Medicine, Cancer Center and Beckman Research Institute, City of Hope Medical Center, Duarte, California, United States of America.
Tae Ju ParkDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Gaeul ChuDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Yunjeong KimDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID https://orcid.org/0000-0003-0870-4320
Kristoffer NikiasDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID https://orcid.org/0009-0002-1717-3285
Cheong-Wun KimDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID https://orcid.org/0000-0002-3229-8935
Dexter Hoi Long LeungDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID https://orcid.org/0000-0003-3210-8131
Chenmiao LiuDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Hong ZengTransgenic, Knockout and Tumor Model Center, Stanford University School of Medicine, Stanford, California, United States of America.ORCID https://orcid.org/0000-0003-3758-5826
Zijie SunDepartment of Cell Biology, Department of Oncology, and Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID https://orcid.org/0000-0002-6787-6272

Funding

Roles of the androgen receptor and its co-regulators in prostate tumorigenesisR01CA070297 · NCI · STANFORD UNIVERSITY · PI SUN, ZIJIE · 2003 to 2025
$5.0M
DNA repair gene mutations and prostate cancerR01CA233664 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SHEN, BINGHUI, SUN, ZIJIE · 2020 to 2024
$3.4M
Wnt responsive stem cells in the prostateR01DK104941 · NIDDK · STANFORD UNIVERSITY · PI SUN, ZIJIE · 2015 to 2024
$3.0M
Aberrant Activation of Androgen Signaling Pathways in African American Prostate CancerR01CA288392 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SUN, ZIJIE · 2024 to 2025
$1.1M
A new and non-autonomous role of androgen signaling in prostate tumorigenesisR01CA289319 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZIJIE SUN · 2025 to 2026
$1.1M
NCI NIH HHS R01 CA070297NCI NIH HHS R01 CA233664NCI NIH HHS R01 CA288392NCI NIH HHS R01 CA289319NIDDK NIH HHS R01 DK104941
6 · The paper itself

Abstract

The androgen receptor (AR) is a nuclear hormone receptor, and its activation through binding to androgens is essential for prostate development, morphogenesis, growth, and tumorigenesis. Although significant efforts have been devoted to understanding the critical role of AR, the cellular properties and functions of the AR-expressing cells acting as prostatic progenitors in controlling prostatic cell differentiation and growth still remain elusive. Additionally, dynamic paracrine interactions between urogenital mesenchyme and epithelia initiated by the AR activation through prostate development are also largely unknown. Recently, we modified the mouse Ar gene locus, which enables us to genetically label AR-expressing cells spatiotemporally and trace them through prostate development, morphogenesis, and growth in combination with a double-fluorescent reporter mouse model. The membrane-bound green fluorescent protein (mGFP)-expressing cells were revealed in both urogenital sinus mesenchyme (UGM) and epithelium (UGE) at embryonic day E18.5 when Tamoxifen was administrated at E13.5 to activate CreER recombinase directed by the endogenous Ar promoter. The AR-expressing cells and their descendants were further detected at postnatal days 10, 35, and 56, and through three cycles of prostatic regeneration by repeated androgen deprivation and replacement. Deletion of β-catenin through the AR-driven CreER in embryonic AR-expressing cells impairs prostate development and morphogenesis. Specifically, altered β-catenin expression results in loss of prostatic glandular cell polarity and activation of Fas death signaling pathways. These lines of experimental evidence demonstrate the biological relevance and significance of this new genetic tool to assess and visualize AR-mediated signaling pathways through prostatic development, growth, and tumorigenesis.

Indexed as

AndrogensMorphogenesisProstateReceptors, AndrogenRegenerationWnt Signaling PathwayAnimalsCell DifferentiationGene Expression Regulation, DevelopmentalMaleMiceSignal TransductionAndrogensAR protein, mouseReceptors, Androgen

Identifiers

PMID40512820
PMCPMC12187012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.